Table 2 Barriers to commercialization/implementation identified during the NIDA I-Corps interviews
Barrier Category | Specific Barrier |
|---|---|
Systemic | • Presence of the X-waiver* • Limited access to insurance coverage for OUD-specific treatment • Laws and consequences of OUD use varying state-by-state |
Patient Care | • Differences in OUD treatment types available based on geographic region • Lack of precision care for OUD • Lack of proper OUD patient surveillance • Need for at-home OD device data collection |
Financial | • OUD patient readmissions are a major cost factor for academic medical centers • Liability and uncertainty regarding funding for OUD innovation |
Social | • Stigma from providers in prescribing MOUD • Limited resources for OUD-based harm reduction services • Psychological unpreparedness toward OUD treatment from patients • Need for a social support structure to prevent OD |